MolecularHealth Adds Chief Medical Officer to New Management Team

  MolecularHealth Adds Chief Medical Officer to New Management Team

Dr. Shelly Gunn brings deep expertise in diagnostic molecular genetics to
MolecularHealth’s executive leadership

Business Wire

THE WOODLANDS, Texas -- September 30, 2013

In a continuation of its plan to commercialize its automated genetic
diagnostic platform for cancer care in the first quarter of 2014,
MolecularHealth announced that it has hired Shelly Gunn, M.D., Ph.D. to serve
as its chief medical officer. The announcement comes on the heels of the
installation of four key members of the company’s U.S. management team.

Dr. Gunn comes to MolecularHealth with an extensive background in diagnostic
molecular genetics, and is recognized as one of the world’s leading experts in
the clinical application of array comparative genomic hybridization (aCGH)
technology, specifically in the areas of breast cancer and hematologic
malignancies. She earned a combined M.D./Ph.D. degree from The University of
Texas Health Science Center at San Antonio (UTHSCSA) Medical School and
Graduate School of Biomedical Sciences, where she also completed her clinical
pathology residency. Prior to joining MolecularHealth, Dr. Gunn founded
Oncopath Laboratory, a genomic pathology reference laboratory located at the
START Center for Cancer Care in San Antonio, Texas.

“Dr. Gunn has spent her career focusing on using genomic testing to provide
personalized care to cancer patients, which aligns her experience perfectly
with our mission,” said Lloyd Everson, M.D., CEO of MolecularHealth. “As we
build out our executive leadership, we are looking for key industry veterans
who bring an extremely high level of expertise in molecular diagnostics, CLIA
lab operations, genomics, and the actionable interpretation of these results
for cancer patients. Dr. Gunn’s background and stature in the community will
be a huge asset to our team.”

Backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP,
MolecularHealth’s genetic diagnostic platform is the result of more than eight
years of development by a multidisciplinary team of doctors, scientists and IT
experts in Heidelberg, Germany. The company is preparing for the commercial
launch of its end-to-end service offering, which walks patients and their
healthcare providers through the molecular diagnostic process—collecting tumor
samples, analyzing the samples in a CLIA-certified lab, and interpreting the
results using a unique analytics platform—all to generate safer and more
targeted cancer treatment choices. As part of its offering, MolecularHealth
will provide patients, oncologists and pathologists with complete logistical
support, including on-call consultations with Dr. Gunn and the Molecular
Health pathology team and help navigating insurance reimbursement for
recommended treatments.

Dr. Gunn said, “The field of molecular diagnostics promises to revolutionize
the treatment of cancer, providing better patient outcomes and quality of
life. MolecularHealth’s end-to-end solution allows doctors to understand the
role that genetics plays in the onset and progression of cancer, providing
them with information drawn from an extensive library of clinical research.
I’m excited to be a part of this breakthrough company, offering a breakthrough
platform in an effort to improve human health.”


MolecularHealth delivers on the promise of personalized, precision medicine.
By using advanced information technologies to sift through terabytes of
genetic and molecular test findings in a fraction of the time needed for
current manual analysis, MolecularHealth provides doctors and patients with
faster, more accurate insights into the role genes play in the progression and
treatment of an individual’s cancer. Eight years in development by a
multidisciplinary team of doctors, scientists and IT experts, MolecularHealth
works in partnership with some of the world’s leading healthcare and
information technology companies, including the University of Texas MD
Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration
(FDA). The company has headquarters in The Woodlands, Texas; Basel,
Switzerland; and Heidelberg, Germany. Visit for more


Gregory FCA
Jessica Attanasio
Associate Vice President
Press spacebar to pause and continue. Press esc to stop.